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Abstract
Background: Increased arterial stiffness is an indicator of mortality. This study consists 
of an 18-month follow-up of the mortality in advanced heart failure patients with increased 
arterial stiffness.
Methods: The study followed up 98 patients with a diagnosis of heart failure in NYHA class 
III and IV (76 males, 22 females and mean age of 60 ± 12 years) with a left ventricular ejection 
fraction ≤ 35% as determined by the Simpson method. Augmentation index (Aix) and pulse 
wave propagation velocity (PWV) parameters were used as indicators of arterial stiffness. Aix 
and PWV values were measured by arteriography. 
Results: 36 patients died. Both Aix and PWV were powerful determinants of mortality, inde-
pendent of other prognostic variables (p = 0.013, OR: 0.805; p = 0.025, OR: 0.853). A cutoff 
value for Aix of –14.33 gave 91.2%, 80.3% sensitivity and specificity. A cutoff value for PWV 
of 11.06 gave 82.4%, 65.4% sensitivity and specificity mortality was predicted. Left ventricular 
ejection fraction (p = 0.008, OR: 0.859) and B-type natriuretic peptide (p = 0.01, OR: 0.833) 
was the other independent determinant of mortality. A significant difference was found in 
both Aix and PWV between the compensated measurements and decompensated heart failure 
measurements made in 70 patients (p = 0.035, p = 0.048).
Conclusions: Measurement of arterial stiffness is a convenient, inexpensive and reliable method 
for predicting mortality in patients with advanced heart failure. (Cardiol J 2013; 20, 6: 665–671)
Key words: heart failure, arterial stiffness, mortality, prognosis
666 www.cardiologyjournal.org
Cardiology Journal 2013, Vol. 20, No. 6
Introduction
Heart failure (HF) is the inability of the heart 
to create sufficient blood flow to meet the metabo-
lic needs of the body [1]. Despite many advances 
in diagnosis and treatment, HF still affects about 
20 million people worldwide [2]. A permanent 
increase in the vascular load as in chronic arterial 
hypertension is a significant cause of HF. Ventricu-
lar failure is quite sensitive to changes in pressure 
and vascular load, and minor increases in vascular 
load can lead to disproportional major reductions 
in the cardiac output [3, 4]. For these reasons, 
vasodilator treatment of HF is common [5, 6].
Many factors have been proposed as indicators 
of survival in HF; however there are as yet no 
adequate trials to show the value of any of these 
variables [7]. This trial was designed to investiga-
te the value of arterial stiffness in predicting the 
prognosis in patients with advanced HF.
Methods
The trial included 98 NYHA stage III–IV pa-
tients (76 males, 22 females and mean age: 59.4 ± 
± 11.6 years) with a left ventricular ejection fra-
ction (LVEF) £ 35% as determined by echocardio-
graphy. All patients had ischemic cardiomyopathy 
due to atherosclerotic heart disease. Patients with 
atrial fibrillation, frequent ventricular extra ectopic 
beats, advanced renal failure (serum creatinine 
> 2.0 mg/dL), hypothyroidism, hyperthyroidism, 
respiratory diseases (COPD, chronic bronchi-
tis, pulmonary embolism), primary pulmonary 
hypertension, acute coronary syndrome within 
the last 2 months, isolated right HF, congenital 
cardiac diseases and advanced valvular disease 
(mitral stenosis, aorta stenosis and failure) were 
excluded from the trial. For patients included in 
the trial, data on risk factors such as age, gender, 
hypertension, diabetes, hyperlipidemia, coronary 
artery disease, smoking, familial history of cardiac 
diseases and drugs received were recorded. The 
patients were questioned for complaints of dys-
pnea, chest pain and palpitations and underwent 
relevant additional investigations. Decompensated 
HF and hospitalization were regarded as morbidity. 
Arterial stiffness measurements were repeated 
during hospitalization. General examination was 
directed to indicate functional incapacity including 
skin paleness, coldness of the limbs, peripheral 
cyanosis and cardiac cachexia. Jugular venous 
distention, hepatomegaly, hepatojugular reflux, 
ascites and pretibial edema were recorded as the 
findings of stasis. Cardiac murmurs and third and 
fourth cardiac sounds were considered to repre-
sent cardiac pathology. Pulse examination of the 
upper and lower limbs was performed. Additional 
investigations were performed in patients with ta-
chycardia. Body mass index (BMI) was calculated. 
Waist circumference over the umbilical line and hip 
circumference including the outmost point of the 
hip were measured. Blood pressure was measured 
by mercury sphygmomanometer. Pulse rate was 
measured over 1-min. 
The patients also underwent 12-lead ECG; 
pathological Q waves, branch blocks, atrial fibril-
lation, ventricular arrhythmias, ST segment and 
T wave changes were noted. Telecardiography 
was performed to investigate cardiac size, pul-
monary parenchymal tissue, pulmonary vascular 
structures, abnormal densities and pleural fluid. In 
addition, whole blood count, fasting blood glucose, 
blood urea nitrogen, creatinine, serum sodium, po-
tassium levels, HDL-cholesterol, LDL-cholesterol, 
total cholesterol, triglyceride levels, albumin, total 
protein, liver, B-type natriuretic peptide (BNP), 
C-reactive protein and thyroid function test mea-
surements were performed. 
The local ethical committee approved this 
study. Informed consent was obtained from all 
patients.
Echocardiography
A detailed echocardiographic examination was 
performed by an experienced technician without 
reference to the clinical findings, using an Acuson 
Sequoia C 256 (General Electric), USA) cardio-
vascular imaging system providing 2-dimensional 
(2D) echocardiography, spectral Doppler and color 
Doppler flow mapping information using a 2.5 or 
3.5 MHz duplex transducer and a 1.9 MHz sound 
only continuous wave Doppler transducer. Standard 
views were obtained with the patient in the left 
lateral position. Images were stored on videotape. 
M-mode, 2D, color flow, and Doppler studies were 
performed on all patients. LV function was assessed 
qualitatively as normal, or as mild, moderate or 
severe dysfunction. Where possible, we calculated 
the EF by the biplane disc summation method 
(Simpson’s rule) [8].
Arterial stiffness measurement
Arterial stiffness was assessed noninvasively 
with the arteriograph (TensioMed, Budapest, 
Hungary) [9]. Oscillometric pulse waves from the 
participants. We measured the distance between 
the jugulum-symphysis (which is the same as by 
the invasive method, the distance between the aor-
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tic root and the aortic bifurcation), and pulse wave 
propagation velocity (PWV) was calculated. Pulse 
waves were recorded at supra-systolic pressure. 
The oscillation signs were identified from the cuff 
inflated at least > 35 mm Hg above the systolic 
blood pressure. In this state brachial artery oc-
clusion was complete; it functions as a membrane 
before the cuff. Pulse waves hit the membrane 
and are measured as oscillometric wave, shown 
on the monitor. The augmentation index (Aix) was 
defined as the ratio of the difference between the 
second (P2 — appearing because of the reflection 
of the first pulse wave) and first systolic peaks 
(P1 — induced by the heart systole) to pulse pressure 
(PP), and was expressed as a percentage of the ratio 
(AI = [P2 – P1] / PP × 100).
During measurements special attention was 
paid to the following: the avoidance of speaking 
muscle movement, especially the arms. Muscle 
movement distorts the shape of the measured pul-
se wave. The patient should not have taken nitrates 
or eaten a large meal, and should avoid black coffee, 
smoking up to 3 h previously and alcohol for 10 h 
before the examination. Sleeping is not allowed! 
Physical and mental relaxation is necessary for at 
least 10 min before measurement. Distractions 
should be avoided during measurement, and com-
plete silence is ideal. If the ‘white coat effect’ is 
suspected, several measurements should be made.
Statistical analysis
All analyses were performed using SPSS sta-
tistical software package version 16.1. Continuous 
variables in the group data are indicated as mean 
± standard deviation (SD). Categorical variables are 
given in numbers and percentages. An independent 
sample t-test and multivariate analysis (ANOVA) 
were performed according to the range of conti-
nuous variables between the groups. For nonpara-
metric tests, Mann-Whitney U and Kruskal-Wallis 
tests were applied. A c2 test was used to compare 
categorical variables. Parametric or nonparametric 
(Pearson and Spearman) correlation analysis was 
performed to identify the relationship between 
continuous variables. Multivariate binary logistic 
regression analysis was performed to identify 
factors affecting mortality. A per unit increase in 
the variables identified from the study increase or 
decrease the risk by a factor specified by the odds 
ratio. ROC analysis was used to determine the cutoff 
value for the variables as predictors in mortality. 
Statistical significance was accepted as p < 0.05.
Results
There were 76 males and 22 females, mean age 
59 ± 11 years; 50 patients had hypertension and 
40 diabetes mellitus; 36 of the patients had died. 
At the 18-month follow-up point all patients or 
a close family member could be contacted. There 
was sudden cardiac death in 24 and decompen-
sation following hospitalization in 12. During the 
follow-up, all 70 patients were hospitalized with 
the diagnosis of decompensated cardiac failure and 
followed up. There were no significant differen-
ces between deceased patients and survivors, or 
hospitalized and non-hospitalized, with respect to 
taking beta-blockers, furosemide, digoxin, spirono-
lactone, statin, or angiotensin receptor blocker and 
angiotensin converting enzyme inhibitor use. The 
demographic characteristics an laboratory findings 
of patients were determined in Table 1.
LV end-systolic and end-diastolic size and 
volume were significantly greater and LVEF was 
significantly lower in those who died and those 
hospitalized (Table 2).
The values of Aix vs. PWV differed signi-
ficantly between the patients who died and the 
survivors, and between the hospitalized and non-
-hospitalized patients. During decompensation, 
Aix and PWV were greater than when the same 
patients were adequately treated (Table 3). 
Deceased patients had a correlation between 
arterial stiffness parameters and BNP, EF, esti-
mated glomerular filtration rate (e-GFR), and 
LV end-diastolic volume. In hospitalized patients 
there was a correlation between arterial stiffness 
parameters and BNP, ejection fraction, and LV end-
-diastolic volume (Table 4).
An independent association between mortality 
and LVEF, BNP, PWV and Aix is shown below the 
logistic regression analysis in Table 5. 
The area under the ROC curve of the rela-
tionship between HF patients’ Aix and mortality 
was 90.7% (Fig. 1). The Aix for all patients was 
found to be a predictor of mortality, with the cutoff 
value at –13.35, with 91.8% sensitivity and 81.9% 
specificity. 
The area under the ROC curve of the relation-
ship between mortality in HF patients and PWV 
was 81.7%. In this analysis the cutoff value for PWV 
as a predictor of mortality was taken as 10.8 with 
83.3% sensitivity and 66.4% specificity. 
The area under the curve of the logistic regres-
sion analysis shows Aix to be a stronger indepen-
dent determinant of mortality than PWV (Fig. 1).
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Discussion
The main finding of our study is that arte-
rial stiffness is a strong predictor of mortality 
in advanced HF, independently of other progno-
stic variables. Previous studies have focused on 
multiple variables to predict the prognosis of HF. 
Decreased systolic and diastolic blood pressure [8], 
increased resting pulse rate [9, 10] and PP [8] are 
all important in the prognosis of HF patients; they 
emerged as important in our study too. 
Natriuretic peptide levels are useful biochemi-
cal markers in diagnosis, risk evaluation and follow 
up in heart diseases [11, 12]. There is a positive 
relationship between plasma natriuretic peptide 
levels and PWV [13, 14]. Kaji et al. [15] reported 
the existence of an association between plasma 
BNP and the radial Aix. Sakaguri et al. [16] sho-
wed a significant relation between BNP and aortic 
stiffness in patients with coronary artery disease. 
In our study BNP concentrations were greater in 
the hospitalized and deceased groups and there was 
Table 2. Echocardiographic findings of deceased and surviving patients.
Echocardiographic findings Deceased  
(n = 36)
Survivor  
(n = 62)
P Hospitalized 
(n = 70)
Non-hospita- 
lized (n = 28)
P
LV end-diastolic size [mm] 65.6 ± 6.6 59.6 ± 3.6 < 0.001 64.1 ± 6.3 60.6 ± 3.2 0.003
LV end-systolic size [mm] 57.8 ± 5.2 49.7 ± 3.9 < 0.001 56.8 ± 6.1 51.7 ± 4.4 0.012
LV end-diastolic volume [mL] 245.6 ± 30.5 199.6 ± 26.7 < 0.001 245.6 ± 30.5 199.6 ± 26.7 < 0.001
LV end-systolic volume [mL] 203.1 ± 27.1 161.9 ± 26.7 < 0.001 198.4 ± 31.1 168.9 ± 31.5 < 0.001
LV ejection fraction [%] 24.7 ± 2.8 28.9 ± 1.9 < 0.001 25.2 ± 2.5 28.8 ± 2.2 0.001
LV — left ventricular
Table 1. Demographic characteristics and laboratory findings of patients.
Characteristics Deceased  
(n = 36)
Survivors 
 (n = 62)
P Hospitalized 
(n = 70)
Non-hospita- 
lized (n = 28)
P
Age [years] 60.5 ± 11.2 59.5 ± 11.3 0.174 59.8 ± 10.7 60.5 ± 10.9 0.233
Sex (female/male) 8%/28% 14%/48% 0.201 15%/70% 7%/28% 0.197
Duration of disease  
[years]
5.4 ± 4.5 4.6 ± 3.1 0.007 5.2 ± 4.4 3.9 ± 2.8 0.022
Hypertension 23 (63.8%) 27 (43.5%) 0.052 36 (51.4%) 14 (50.0%) 0.612
Diabetes 15 (41.6%) 25 (40.3%) 0.116 28 (40.0%) 12 (42.8%) 0.153
Smoker 26 (58.8%) 25 (47.1%) 0.145 34 (48.6%) 25 (57.4%) 0.235
BMI [kg/m2] 26.4 ± 3.8 26.2 ± 4.1 0.085 26.1 ± 3.9 26.4 ± 3.8 0.108
SBP [mm Hg] 125 ± 20 146 ± 26 < 0.001 128 ± 22 143 ± 21 < 0.001
DBP [mm Hg] 75.7 ± 8.8 87.4 ± 16.1 < 0.001 77.9 ± 9.1 85.4 ± 14.6 < 0.001
Mean BP [mm Hg] 107 ± 18.9 92.2 ± 11.3 < 0.001 106 ± 17.9 91.4 ± 10.8 < 0.001
Pulse pressure [mm Hg] 50.7 ± 15.4 40.9 ± 6.5 < 0.001 52.6 ± 14.6 43.9 ± 6.7 < 0.001
Pulse [bpm] 86.8 ± 13.4 75.0 ± 14.6 < 0.001 85.2 ± 12.5 74.0 ± 13.9 < 0.001
Leukocyte [µL] 8.1 ± 2.7 8.3 ± 2.5 0.670 8.5 ± 2.9 8.0 ± 2.4 0.324
Hemoglobin [g/dL] 12.2 ± 2.5 12.9 ± 3.0 0.686 11.5 ± 3.1 12.9 ± 3.1 0.233
Hematocrit [%] 36.3 ± 6.1 39.1 ± 5.6 0.774 34.1 ± 4.6 36.4 ± 6.5 0.512
Glucose [mg/dL] 148 ± 105 138 ± 70 0.135 142 ± 73 144 ± 115 0.188
BUN [mg/dL] 31.3 ± 10.2 23.6 ± 12.4 0.004 30.3 ± 9.9 27.1 ± 12.6 0.011
Creatinine [mg/dL] 1.3 ± 1.8 1.4 ± 0.4 0.003 1.3 ± 1.7 1.3 ± 1.2 0.006
Sodium [mmol/L] 135.3 ± 4.5 139 ± 4.0 < 0.001 135.1 ± 4.7 139.3 ± 4.5 < 0.001
Potassium [mmol/L] 4.6 ± 0.8 4.5 ± 0.5 0.533 4.6 ± 0.5 4.6 ± 0.9 0.463
Total protein [mg/dL] 7.6 ± 0.6 7.8 ± 0.9 0.330 7.5 ± 0.9 7.7 ± 1.0 0.228
BNP [pg/mL] 6215 ± 3745 2562 ± 2723 < 0.001 5473 ± 4013 4167 ± 3750 < 0.001
e-GFR 47.2 ± 9.5 56.3 ± 14.8 < 0.001 48.8 ± 13.4 53.2 ± 10.6 < 0.001
BMI — body mass index; BP — blood pressure; BUN — blood urea nitrogen; BNP — B type natriuretic peptide; e-GFR — estimated glome-
rular filtration rate; DBP — diastolic blood pressure;  SBP — systolic blood pressure
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a significant correlation between arterial stiffness 
indicators. In multivariate analysis of laboratory 
values, BNP levels were an independent prognostic 
determinant of mortality. 
Table 3. Comparison of the pulse wave velocity 
(PWV) and the augmentation index (Aix) values  
between the deceased vs. surviving patients,  
hospitalized vs. non-hospitalized patients and 
compensation vs. decompensation.
Aix [%] PWV [m/s]
Deceased  
(n = 36)
4.2 ± 17.8 13.8 ± 2.9
Survivor  
(n = 62)
–31.3 ± 18.8 10.2 ± 2.2
P < 0.001 < 0.001
Hospitalized  
(n = 70)
–15.2 ± 26.7 11.9 ± 3.2
Non-hospitalized  
(n = 28)
–25.3 ± 17.4 10.8 ± 2.5
P 0.035 0.048
Decompensation  
(n = 70)
1.8 ± 18.4 11.9 ± 3.2
Compensation  
(n = 70)
–15.2.2 ± 26.7 9.8 ± 3.1
P < 0.001 < 0.001
Renal insufficiency, common in patients with 
HF, worsens the prognosis [17–20]. The present 
results agree with the hypothesis that mild im-
pairment of renal function might increase arterial 
stiffness. Schillaci et al. [21] found that decreased 
Table 4. Correlation analysis of augmentation index and pulse wave velocity.
Deceased Aix brachial 
[%]
PWV 
[m/s]
Hospitalized Aix brachial 
[%]
PWV  
[m/s]
BNP [pg/mL] r 0.479 0.343 r 0.384 0.312
p 0.000 0.001 p 0.000 0.004
e-GFR r 0.398 0.321 r –0.197 –0.182
p 0.001 0.003 p 0.068 0.092
LVEF [%] r –0.471 –0.442 r –0.284 –0.235
p 0.000 0.000 p 0.012 0.028
LVEDV [mL] r 0.422 0.389 r 0.278 0.222
p 0.000 0.001 p 0.009 0.039
Aix — augmentation index; BNP — B-type natriuretic peptide; e-GFR — estimated glomerular filtration rate; LVEDD — left ventricular end-
-diastolic volume; LVEF — left ventricular ejection fraction; PWV — pulse wave velocity
Table 5. Independent determinants of mortality in patients with heart failure; age adjusted odds ratio 
were given.
Odds ratio 95% confidence interval P
Augmentation index [%] 1.128 1.026–1.240 0.013
Pulse wave velocity [m/s] 1.244 1.042–1.385 0.025
Left ventricular ejection fraction [%] 0.859 0.775–0.951 0.008
B-type natriuretic peptide [pg/mL] 1.152 1.051–1.262 0.01
Figure 1. ROC curve.
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e-GFR was a major determinant of accelerated 
progression of central and peripheral arterial 
stiffness in hypertensive patients with normal 
renal function. Kwamato et al. [22] showed that 
decreased e-GFR is associated with an increased 
risk of increased PWV in the general population. 
Decreased GFR, and increased blood urea nitrogen 
and creatinine levels are significant prognostic 
factors for HF. In our study, e-GFR was lower in ho-
spitalized patients and non-survivors; in the latter 
it was correlated to arterial stiffness. In multiva-
riate analysis, e-GFR appeared as an independent 
prognostic determinant of mortality. 
LV systolic and diastolic dysfunction in HF 
impact on mortality. LVEF is an objective and 
independent variable in the prognosis of HF [23]. 
An association between LV diastolic and systolic 
end size and volumes, LV mass index, left atrium 
diastolic size and volumes and mortality has been 
shown, though these indicators did not act indepen-
dently [24–26]. We found an association between 
mortality and several echocardiographic variables; 
however, an independent association with mortality 
was found only with LVEF. There was a correlation 
between echocardiographic LVEF and LV end-
-diastolic volume and markers of arterial stiffness. 
Many previous trials have assessed the progno-
stic importance of PWV in hypertension, diabetes, 
end-stage renal failure and in the elderly. In an epi-
demiological trial by Willum-Hansen et al. [27], the 
associations of PWV increase with the cardiovascular 
disease risk and increased mortality was demon-
strated. In the Framingham cardiac trial, individuals 
with a high PWV value had a greater risk of cardio-
vascular disease mortality [7]. Our study is the first 
in which arterial stiffness was evaluated at the start 
of the trial in patients with systolic HF; arterial load 
is an important factor in the development of HF [3]. 
There is increased arterial stiffness and a decreased 
aortic flexibility in HF [28–32]. Arnold et al. [32] 
reported increased PWV in patients with moderate/ 
/advanced HF. Increased brachial and aortic stiffness 
increase the amplitude of the reflected pressure wave 
in patients with HF [29]. An increase in arterial 
stiffness is significant for mortality and the finding 
of recurrent myocardial infarction in patients with 
LV dysfunction after infarction [33]. By causing 
an increase in PWV, stiff conduit vessels cause the 
reflected wave to return in late systole rather than 
in diastole, impeding the forward systolic wave mo-
tion. An additional load is thus imposed on the LV, 
which can lead to decompensation and arrhythmias. 
Aix and PWV were strong predictors of mortality in 
non-survivors. They were also independent of other 
prognostic variables. Non-survivors had significantly 
greater arterial stiffness than those who survived. 
Increased arterial stiffness is associated with 
decompensation [34, 35]. In patients with a low EF, 
the renin–angiotensin–aldosterone system and 
inflammatory mediators increase in activity, resul-
ting in increased water and salt retention. This in 
turn leads to a further increase in arterial stiffness 
[34–37]. Renal function deteriorates, the response 
to diuretics is decreased, ventricular workload is 
increased, and the decompensation process acce-
lerates [35, 37]. Our study showed that PWV and 
Aix were significantly lower when treatment was 
adequate; arterial stiffness was always greater in 
hospitalized patients. 
Conclusions
We found measurement of arterial stiffness to 
be a convenient, inexpensive and reliable method for 
predicting mortality in patients with advanced HF. In 
addition, it could also be used in outpatients with HF 
to optimize treatment and thus avoid hospitalization. 
Limitations of the study
Ninety-eight patients were included in our 
study. Therefore, studies with larger sample sizes 
are needed. The occurrence of ventricular and su-
praventricular arrhythmias adversely affect cardiac 
output in patients with HF, and we could not evalu-
ate the patients with arrhythmias by arteriograph. 
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